In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

‘We’re On The Edge Of Knowledge,’ Says Dewpoint CEO

Executive Summary

Biomolecular condensates were first observed over 100 years ago, but their function – and the role they might play in a broad range of diseases – is only now being rigorously explored by drug developers. New technological development is helping scientists recreate condensates in laboratory conditions, providing insight into fundamental cellular processes. Amir Nashat, CEO of Dewpoint Therapeutics, told In Vivo that the company, following a recent $77m series B round, now has the resources to get to proof of concept for drugs targeting biomolecular condensates.

You may also be interested in...



Managing The Expansion of Clinical Trial Data Sources

Increases in remote patient monitoring and decentralized clinical trials – accelerated by COVID-19 – have added complexity to data management systems. Traditional platforms and electronic data capture used by drug development sponsors are ineffectual tools for integrating new primary data sources, or managing remote patient monitoring, Raj Indupuri, CEO at eClinical Solutions told In Vivo. 

Digital Acceleration: Low-Hanging Fruit And Stretch Goals

COVID-19 has pushed the entire health care system to adopt new technologies and new solutions for conducting clinical research and delivering care to patients. An expert panel hosted by the Galien Foundation provided a meditation on what the biopharma industry has learned so far, and how to use the urgency created by COVID-19 to lock-in technological acceleration while maintaining what FDA’s Amy Abernethy called  “responsible progress.”

Finding The Exit: Forbion On Roche’s Acquisition Of Inflazome

Two years after leading a $46m series B financing round in Inflazome, a four-year old Irish biotech developing oral NLRP3 inflammasome inhibitors, VC firm Forbion is celebrating Roche’s $446m acquisition of the company, which includes the potential for additional milestone payments. Forbion general partner Marco Boorsa, who joined Inflazome’s board of directors in November 2018, spoke with In Vivo about the VC firm’s investment strategy.

Topics

Related Companies

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel